## Smith-Nephew

## Meet the Management 2023

Orthopaedics 29 November



### Our journey to rewire Orthopaedics for sustainable growth and improved profitability





### **Rewiring Orthopedics**

- Improvement in supply and demand processes
- + Enhancing our commercial operations
- + Commercial incentives realigning from retention to growth
  - Network optimisation to right-size capacity

### **Positioned for success**


- + Deliver sustainable growth
- Recapture share in Recon, gain share in Trauma
  - + Improved profitability
- + Improved working capital intensity

### **Our starting point**

- Supply & demand disconnected and high levels of inventory
  - Portfolio gaps requiring R&D investment
    - + Excess capacity
- Underperformance versus market since COVID


## Sizeable \$27bn global Orthopaedics market opportunity





## **Market trends impacting Orthopaedics**







Increasing adoption of enabling technology

**Prioritising tech** that offers surgical efficiency and flexibility



### Patient

Patients living longer at higher levels of activity



### **Providers**

Pervasive price pressure, staffing, payer delays Continued site-of-care

shift to ASC/short-stay market

### **Our new value proposition supports a unified strategy**



# Precision :

An uncompromising commitment to freedom of movement

Strategic Pillars

Surgery Personalized Efficiency Advanced Performance Optimized



### Levers to execute near-term strategies





### Leading procedural transformation with CORI<sup>¢</sup>



### **CORI** unlocks the value of robotics

- New AI enabled surgical techniques
- Novel implant designs

Closed-loop data capture

Less capital required



### Differentiated robotics platform

- Most versatile system with procedural flexibility
- Suitable for any surgical location: "One OR, One CORI"
- Most scalable platform
- Market development and commercial execution

### **Demonstrated success**

- CORI penetration in leading Academic Centers and ASCs
- First to market with knee revision, AI, and soft-tissue balancing
- Increase in multi-facility deals

- 25% utilisation in US knee procedures
- Market leading installations in EMEA
- ~50% YoY increase in new global installs



## **CORI** is the most novel, flexible and scalable solution

C	

Key Features	SmithNephew	Competitor #1	Competitor #2	Competitor #3
Robotic-assisted capabilities		$\checkmark$		~
Small OR footprint Suitable for ORs with limited space	Small 9.1 kg	<b>Large</b> 400kg	<b>Large</b> 500kg	<b>Medium</b> > 75kg*
<b>Portability</b> Easily moved between operating theatres	V High	<b>Low</b> 3 separate carts	<b>Low</b> 2 separate carts	<b>Low</b> 2 separate carts
<b>Quick set up time</b> Minimises procedure time	5 minutes	30 - 45 minutes	20+ minutes	15+ minutes
Pre-surgical imaging protocol	Available, Not Required 3D Intra-operative mapping	Required	Required	Not Required
Total Knee Resection options	Precision Milling & Tibial Saw Enablement	Saw only	Saw only	Saw only
AI enablement (intra-op)	Personalised Planning	×	x	х
Balancing solutions	Digital Tensioner  Pre-cut tensioning device	Requires bone cuts before use	Manual	<b>Manual</b> Mechanical tensor post tibia cut
Indications as of 2023	<b>Knee:</b> Partial, Primary, XR, <b>Revisior</b> <b>Hip:</b> Primary	Knee: Partial, Primary, PFJ Hip: Primary	Knee: Partial, Primary Hip: Primary	Knee: Primary

✓ New since 2021 Investor Day

Sources:

Smith+Nephew: Internal Documentation – Data on file with S+N Other competitors: manufacturers websites, and instructions for use. \*complete system weight.

## Industry leading designs, materials, and robotics technology SA



## Highly differentiated in largest segment of knees





#### **Differentiated performance**

Leverageable OXINIUM\* Material and Kinematics

CORI<sup>+</sup> + JOURNEY II + OXINIUM delivers premium mix and performance advantage Personalised surgeries with CORI knee Tensioner and JOURNEY design

## Advancing hip with best-in-class bearing surface and advanced technologies



### Best in class bearing performance and hip stability

Validated by registry data

### Personalised, technology enabled hip procedures

Procedures enabled with CORI<sup>o</sup> platform

### **Strengthening portfolio**

#### Launching Catalyst Short Stem in 2024 for Direct Anterior Approach

OR30<sup>(</sup> Dual Mobility with OXINIUM<sup>®</sup> DH Technology





POLAR3<sup>©</sup> Total Hip Solution with OXINIUM® Technology



RI.HIP CORI<sup>\$</sup> + RI.HIP MODELER





## Differentiated EVOS<sup>4</sup> system driving growth in \$4.7bn Plate & Screw sub-segment



### **EVOS Plating System**

#### **Simplicity**

Comprehensive plating system that addresses all fragment surgical needs

### Efficiency

Streamlined instrument design and advanced implant solutions that benefit the surgeon and hospital system



2014

**EVOS MINI** 








2022 EVOS LARGE

### **EVOS system is driver of core trauma**




- Enhanced SIOP\* process improves service levels
- Acceleration of set deployments
- EVOS LARGE provides full portfolio to capture share
- Strong commercial execution on robust pipeline

## AETOS<sup>\$</sup> offers differentiators to drive share gain

Entry into \$1.7bn Shoulder Market with 9.5% CAGR





## **Rebuilding operations capabilities and performance**





### **Our starting point**

- Ineffective and poorly understood SIOP\* process
  - + Over ordering inventory
- Capability gaps leading to poor decision making
- Building capacity too far ahead of market demand

### **Building market back**

- Established new SIOP process and launched supporting systems capability
- New team members hired for industry and functional knowledge
- Balanced scorecard thinking, focused on Revenue, Cost and Cash
  - + Completed full network review

### **Positioned for success**

- Significant production cut burning down excess inventory, with >70% reduction to overdue orders
- Headcount actions in every facility,
  2 plant closures in execution stage
- Reduced budgeted ops capex by
  >40% in 2 years, no quality impact
- Rolling out a comprehensive Lean / Operations excellence program

\*SIOP: Sales, Inventory and Operations Planning

### Significant progress to evolve our commercial execution

### **Key enhancements:**

- + Shifted to business unit led model
- + Incentives are growth-oriented rather than retention-oriented
- Rebalanced territories, mapped to opportunity
- General Managers leading integrated Recon and Trauma business units in the US
- New leadership and dedicated team for Ambulatory Surgery Center strategy
- Reallocated inventory to optimise asset utilisation

### **Speakers**





**Brad Cannon** President, Orthopaedics

- Over 30 years of experience across medical devices and medtech
- Undertaken a number of executive roles at S+N, including leading the Sports Medicine and ENT franchise
- Previously responsible for Medtronic's Spine division
- MBA from The Wharton School, University of Pennsylvania



**Paul Connolly** President, Global Operations

- Over 30 years of experience in global manufacturing and supply chain with a strong track record in delivering operational excellence and transformation programmes
- Held senior roles at Goodyear, DePuy, and other Johnson & Johnson family companies
- MSc in Manufacturing Management from Ulster University



**Craig Gaffin** SVP and General Manager, Trauma and Extremities

- 25 years of experience in medical devices and biotechnology
- Held a number of commercial leadership roles, including at Stryker and Amgen prior to joining S+N in 2019
- MBA from the Olin School of Business at Washington University, St. Louis



Andy Russell Chief Financial Officer, Orthopaedics

- Joined S+N in 2013 following a 17-year career at KPMG in London, with a focus on Healthcare M&A
- Held a range of senior finance roles across S+N, in Corporate and Commercial Finance, and as CFO of EMEA
- Most recently served as interim President of the EMEA region

## Smith-Nephew